Michael E. Thase is Professor of Psychiatry in the Department of Psychiatry of the Perelman School of Medicine of the University of Pennsylvania, where he is a member of the medical staffs of the Hospitals of the University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center and Director of Penn Psychiatry’s Mood and Anxiety Section.
A 1979 graduate of The Ohio State University College Medicine, he completed internship at the University of Pittsburgh Medical Center (UPMC) and residency, chief residency, and post-doctoral training in clinical research at UPMC’s Western Psychiatric Institute and Clinic. Joining the faculty of the UPMC’s Department of Psychiatry in 1983, he was Professor of Psychiatry and Chief of the Division of Academic Adult Psychiatry when he moved to Philadelphia in 2007.
Board certified in General Adult Psychiatry and a Distinguished Life Fellow of the American Psychiatric Association, Professor Thase is renowned as a teacher, mentor, administrator, researcher and clinician. He has been elected to the membership of the American College of Psychiatrists and Penn Medicine’s Academy of Master Clinicians. Professor Thase also has been elected as first a member and then a fellow of the American College of Neuropsychopharmacology. He is the immediate Past President and a member of the Board of Directors of the American Society of Clinical Psychopharmacology, a Founding Fellow of the Academy of Cognitive Therapy, and a member of advisory boards for the Anxiety and Depressive Disorders Association, the National Network of Depression Centers, the Depression and Bipolar Support Alliance and the American Foundation for Suicide Prevention.
One of the world’s most highly cited psychiatrists, Professor Thase’s 900+ scholarly papers include a number of citation classics. The award-winning Learning Cognitive Therapy is among the 18 books that Professor Thase has authored, co-authored or co-edited. Professor Thase’s research has been continuously funded since the mid-1980s and currently focuses on novel pharmacotherapies for depressive disorders and dissemination and implementation of cost-effective forms of cognitive behavior therapy.